PR Newswire Clinical TrialsOriginal article
Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance
RegulatoryapprovedpidnarulexPositive
AI Analysis
Summary
Senhwa Biosciences announced that the Taiwan FDA has cleared a Phase 1b/2a clinical trial evaluating pidnarulex (CX-5461) in combination with a PD-1 inhibitor for immuno-oncology. This represents a significant regulatory milestone enabling the company to advance its combination therapy approach.
Clinical Trial Data
Phase
1b/2a
Outcome Details
Taiwan Food and Drug Administration (TFDA) cleared the multicenter Phase 1b/2a clinical trial
Importance:6/10
Sentiment:
0.70
immuno-oncologyPhase 1b/2acombination therapyPD-1 inhibitorclinical trial clearanceTaiwan FDA
Read the original article
Published by PR Newswire Clinical Trials on August 6, 2026 9:14 AM